Showing 1–2 of 2 results for author: Cangea, C
-
Structure-aware generation of drug-like molecules
Authors:
Pavol Drotár,
Arian Rokkum Jamasb,
Ben Day,
Cătălina Cangea,
Pietro Liò
Abstract:
Structure-based drug design involves finding ligand molecules that exhibit structural and chemical complementarity to protein pockets. Deep generative methods have shown promise in proposing novel molecules from scratch (de-novo design), avoiding exhaustive virtual screening of chemical space. Most generative de-novo models fail to incorporate detailed ligand-protein interactions and 3D pocket str…
▽ More
Structure-based drug design involves finding ligand molecules that exhibit structural and chemical complementarity to protein pockets. Deep generative methods have shown promise in proposing novel molecules from scratch (de-novo design), avoiding exhaustive virtual screening of chemical space. Most generative de-novo models fail to incorporate detailed ligand-protein interactions and 3D pocket structures. We propose a novel supervised model that generates molecular graphs jointly with 3D pose in a discretised molecular space. Molecules are built atom-by-atom inside pockets, guided by structural information from crystallographic data. We evaluate our model using a docking benchmark and find that guided generation improves predicted binding affinities by 8% and drug-likeness scores by 10% over the baseline. Furthermore, our model proposes molecules with binding scores exceeding some known ligands, which could be useful in future wet-lab studies.
△ Less
Submitted 7 November, 2021;
originally announced November 2021.
-
Structure-Based Networks for Drug Validation
Authors:
Cătălina Cangea,
Arturas Grauslys,
Pietro Liò,
Francesco Falciani
Abstract:
Classifying chemicals according to putative modes of action (MOAs) is of paramount importance in the context of risk assessment. However, current methods are only able to handle a very small proportion of the existing chemicals. We address this issue by proposing an integrative deep learning architecture that learns a joint representation from molecular structures of drugs and their effects on hum…
▽ More
Classifying chemicals according to putative modes of action (MOAs) is of paramount importance in the context of risk assessment. However, current methods are only able to handle a very small proportion of the existing chemicals. We address this issue by proposing an integrative deep learning architecture that learns a joint representation from molecular structures of drugs and their effects on human cells. Our choice of architecture is motivated by the significant influence of a drug's chemical structure on its MOA. We improve on the strong ability of a unimodal architecture (F1 score of 0.803) to classify drugs by their toxic MOAs (Verhaar scheme) through adding another learning stream that processes transcriptional responses of human cells affected by drugs. Our integrative model achieves an even higher classification performance on the LINCS L1000 dataset - the error is reduced by 4.6%. We believe that our method can be used to extend the current Verhaar scheme and constitute a basis for fast drug validation and risk assessment.
△ Less
Submitted 21 November, 2018;
originally announced November 2018.
